White Alexandra J, Almeida João Paulo, Filho Leonardo Macedo, Oyem Precious, Obiri-Yeboah Derrick, Yogi-Morren Divya, Kshettry Varun R, Recinos Pablo F
Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida, USA.
World Neurosurg. 2024 Nov;191:205-212. doi: 10.1016/j.wneu.2024.08.090. Epub 2024 Sep 7.
There is a well-documented association between Cushing's syndrome (CS) and hypercoagulability. However, there is limited data on the risk of venous thromboembolic events (VTEs) after surgery for Cushing's disease (CD). There is no consensus on optimal postoperative anticoagulation strategies in this group. This review gathers information on the rates of VTE after surgery for CD, as well as reported prophylaxis strategies in this population.
A literature search was performed using Cochrane Library, EMBASE, and Ovid MEDLINE databases according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A narrative review of papers discussing mechanisms of hypercoagulability in CS was conducted.
Twenty-five relevant papers were identified out of 944 papers yielded. Pooled postoperative VTE incidence in patients undergoing transsphenoidal surgery for CD was 2% (58 out of 2997). The pooled rate of VTE-associated mortality based on the 23 studies that reported this information was 0.2% (6 out of 2077). There were no cases of postoperative VTE in the 191 patients undergoing adrenalectomy for benign adrenocorticotropic hormone-independent CS. Ten studies reported information on perioperative thromboprophylaxis strategies in transsphenoidal surgery for CD and adrenalectomy for adrenocorticotropic hormone-independent CS.
Postoperative VTE in CD is a source of morbidity, with a rate of 2% and mortality rate of 0.2%, highlighting that surgical resection of the corticotroph adenoma does not necessarily result in immediate resolution of hypercoagulability. Increased production of coagulation factors, impaired fibrinolysis, inflammation, and CS-associated metabolic risk factors all factor into the pathogenesis of CS-associated hypercoagulability. Further study is needed on an optimal pharmacologic prophylaxis strategy.
库欣综合征(CS)与高凝状态之间的关联已有充分记录。然而,关于库欣病(CD)手术后发生静脉血栓栓塞事件(VTE)的风险数据有限。对于该群体术后最佳抗凝策略尚无共识。本综述收集了CD手术后VTE发生率以及该人群中报告的预防策略的相关信息。
根据系统评价和Meta分析的首选报告项目指南,使用Cochrane图书馆、EMBASE和Ovid MEDLINE数据库进行文献检索。对讨论CS高凝机制的论文进行叙述性综述。
在检索出的944篇论文中,确定了25篇相关论文。接受经蝶窦手术治疗CD的患者术后VTE合并发生率为2%(2997例中有58例)。根据报告该信息的23项研究,VTE相关死亡率的合并率为0.2%(2077例中有6例)。191例因良性非促肾上腺皮质激素依赖性CS接受肾上腺切除术的患者中未发生术后VTE。10项研究报告了经蝶窦手术治疗CD和非促肾上腺皮质激素依赖性CS肾上腺切除术围手术期血栓预防策略的信息。
CD术后VTE是发病的一个原因,发生率为2%,死亡率为0.2%,这突出表明切除促肾上腺皮质激素腺瘤不一定能立即消除高凝状态。凝血因子产生增加、纤维蛋白溶解受损、炎症以及与CS相关的代谢危险因素均参与了CS相关高凝状态的发病机制。需要进一步研究最佳的药物预防策略。